Patents Assigned to Shanghai Hengrui Pharmaceutical Co., Ltd.
  • Patent number: 10906905
    Abstract: The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring bridged ring derivative as shown in formula (I), a preparation method therefor and a pharmaceutical composition comprising the derivative, and the use thereof as a therapeutic agent, in particular as a TGF-? inhibitor, and the use in the preparation of a drug for treating, preventing or reducing cancers mediated by the over-expression of TGF-?, wherein the definition of each substituent in the general formula (I) is the same as defined in the description.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 2, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai Yu, Fanglong Yang, Jingjing Yan, Xiao Wu, Feng He, Weikang Tao
  • Patent number: 10899741
    Abstract: The present invention relates to a 3,4-bipyridyl pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new 3,4-bipyridyl pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, a use of the derivative as a therapeutic agent, in particular as a TGF-? inhibitor, and a use of the derivative in the preparation of a drug which treats, prevents or reduces cancer mediated by TGF-? overexpression. The substituents in formula (I) have the same definitions as in the description.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: January 26, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Guangyuan Shen, Feng He, Weikang Tao
  • Patent number: 10899837
    Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: January 26, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jinming Gu, Xiaohua Wang, Xin Ye, Liuqing Yang, Ting Zhang, Weikang Tao, Lianshan Zhang
  • Patent number: 10889569
    Abstract: A condensed ring group azacyclobutyl triazole derivative, a preparation method therefor and use thereof in medicine are provided. In particular, a condensed ring group azacyclobutyl triazole derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, use thereof as a therapeutic agent, in particular as an oxytocin antagonist, and for treating or preventing a disease or a condition that is known or can exhibit a beneficial effect of inhibiting oxytocin are provided. The definition for each substituent in general formula (I) is the same as that in the description.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 12, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Wei He, Bin Wang, Zhigao Zhang, Feng He, Weikang Tao
  • Patent number: 10857146
    Abstract: A method for preventing or treating tumor diseases with a combination of a tyrosine kinase inhibitor and a CDK4/6 inhibitor is provided. In particular, a method for preventing or treating tumor diseases, including administering to a patient a tyrosine kinase inhibitor of a compound of formula (I), or a complex, a pharmaceutically acceptable salt or a stereoisomer thereof and a CDK4/6 inhibitor is provided.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: December 8, 2020
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Jiahua Jiang, Cheng Liao, Lianshan Zhang, Piaoyang Sun, Lin Shen, Jing Gao, Jifang Gong
  • Publication number: 20200369774
    Abstract: Provided in the present invention are an IL-6R antibody and antigen-binding fragment thereof. The IL-6R antibody is an alpaca-derived antibody, chimeric antibody and humanized antibody. Also provided in the present invention is the use of the antibody in the preparation of a drug for treating IL-6-related diseases.
    Type: Application
    Filed: September 12, 2018
    Publication date: November 26, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Hua Ying, Houcong Jin, Qiyue Hu, Hu Ge, Yifang Wang, Weikang Tao
  • Publication number: 20200339692
    Abstract: A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.
    Type: Application
    Filed: January 9, 2019
    Publication date: October 29, 2020
    Applicants: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xiaoling GU, Jiahua JIANG, Lei ZHANG, Qiyue HU, Jinming GU, Weikang TAO
  • Patent number: 10815304
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 27, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • Patent number: 10793643
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 6, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Xin Ye, Shaoyu Xu, Bei Yuan, Dongbing Cui, Qiyue Hu, Lei Zhang, Zhibin Xu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Publication number: 20200277278
    Abstract: A deuterium atom-substituted indole formamide derivative, a preparation method therefor, and medical applications thereof. Specifically, the present invention relates to a deuterium atom-substituted indole formamide derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and uses of the derivative serving as an ROR agonist and uses of the derivative in preventing and/or treating tumors or cancers, definitions of substituent groups in general formula (I) being same as definitions in the specification.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Dong Liu, Lei Chen, Biao Lu, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Patent number: 10759787
    Abstract: The present invention relates to a benzofuran derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to the benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, wherein the definitions of the substituents in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: September 1, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Biao Lu, Xiaodong Shen, Mingxun He, Dong Liu, Minsheng Zhang
  • Patent number: 10759788
    Abstract: Pharmaceutical uses of pyridinecarboxamide derivatives are provided. In particular, pharmaceutical uses of pyridinecarboxamide derivatives represented by general formula (I), wherein the substituents of the formula (I) are defined in the specification, are provided. The pyridinecarboxamide derivatives can be used as therapeutic agents, especially as inhibitors of the Renal Outer Medullary Potassium channel (ROMK) and in the preparation of medicaments for treating and/or preventing ROMK mediated disorders, such as hypertension and heart failure.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 1, 2020
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xin Li, Qing Dong, Piaoyang Sun
  • Patent number: 10633375
    Abstract: The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 28, 2020
    Assignees: Jinagsu Hengrui Medicine Co., Ltd, Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Weimin Wang, Xiaodong Li, Gang Chen, Feng He, Weikang Tao
  • Patent number: 10633388
    Abstract: Pyrazolopyrimidone derivatives and methods of use thereof are described. Specifically, pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: April 28, 2020
    Assignees: Shanghai Hengrui Pharmaceutical Co., ltd., Jiangsu Hangrui Medicine Co., Ltd.
    Inventors: Hejun Lu, Piaoyang Sun, Bin Gui, Qing Dong
  • Publication number: 20200055852
    Abstract: The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring bridged ring derivative as shown in formula (I), a preparation method therefor and a pharmaceutical composition comprising the derivative, and the use thereof as a therapeutic agent, in particular as a TGF-? inhibitor, and the use in the preparation of a drug for treating, preventing or reducing cancers mediated by the over-expression of TGF-?, wherein the definition of each substituent in the general formula (I) is the same as defined in the description.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 20, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai YU, Fanglong YANG, Jingjing YAN, Xiao WU, Feng HE, Weikang TAO
  • Patent number: 10562977
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: February 18, 2020
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali Wang, Lianshan Zhang, Jindong Liang, Ang Li, Fanglong Yang
  • Patent number: 10543284
    Abstract: Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: January 28, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jiajian Liu, Lianshan Zhang, Weikang Tao, Yayuan Fu, Ling Zhang, Dong Ma, Dongbing Cui, Yali Wang, Jianyan Xu, Jindong Liang, Ying Zhang, Guiyang Jiang, Junzhuan Qiu, Ziyong Sun, Jiping Zha, Jingping Wei
  • Patent number: 10513510
    Abstract: The present invention relates to a new toxin and a method for preparing an intermediate thereof. In particular, the present invention relates to a new toxin and a method for preparating intermediates of Formula (III) and Formula (IV) thereof, and a preparation method for synthesizing what is shown in general formula (I). The method comprises subjecting a chiral compound shown in general formula (III) to a series of protecting group additions, protecting group removal and amidation so as to obtain a compound as shown in general formula (I). The present method has the advantages of mild reaction conditions, simple operation, high optical purity and high synthetic yield, and thus is suitable for large-scale production.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: December 24, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jianyan Xu, Ying Zhang, Bolei Qu, Guiyang Jiang
  • Patent number: 10449250
    Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: October 22, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jiajian Liu, Yayuan Fu, Haoying Zhang, Yifang Wang, Zhen Zhang, Ling Zhang, Dongbing Cui, Lianshan Zhang, Weikang Tao
  • Patent number: 10442794
    Abstract: Processes for preparing pyridinecarboxamide derivatives are provided. In particular, process for preparing pyridinecarboxamide derivatives represented by general formula (I) are provided, wherein the substituents of the formula (I) are defined in the specification.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: October 15, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Qing Dong, Piaoyang Sun